Granted Patent
B2
US 12,552,765 · App. 17/120,800 · Granted Feb 17, 2026
Small molecule modulators of pantothenate kinases
Inventors:
Lalit Kumar Sharma (South San Francisco, CA); Richard E. Lee (Cordova, TN); Charles O. Rock (Bartlett, TN); Suzanne Jackowski (Bartlett, TN); Mi Kyung Yun (Collierville, TN); Chitra Subramanian (Cordova, TN); Jiuyu Liu (Collierville, TN)
C07D401/04A61K31/501A61P3/10A61P25/00C07D213/85C07D237/24C07D241/04C07D401/12C07D401/14C07D403/04C07D403/12C07D409/12C07D409/14C07D413/14
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure relates to chemical compounds that modulate pantothenate kinase (PanK) activity for the treatment of metabolic disorders (such as diabetes mellitus type II), neurologic disorders (such as pantothenate kinase-associated neurodegeneration), pharmaceutical compositions containing such compounds, and their use in treatment. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Claims (16)
1 . A method of increasing pantothenate kinase activity in a subject, comprising providing to the subject an effective amount of a compound having a structure represented by a formula:
or a pharmaceutically acceptable salt thereof,
wherein A is CH 2 ;
Q 1 is CH, and wherein R 2 is selected from —SCH 3 , C1-C8 acyclic alkyl, C2-C8 acyclic alkenyl, C1-C8 monohaloalkyl, C1-C8 polyhaloalkyl, C1-C8 alkoxyhaloalkyl, cyclopropyl, cyclobutyl, and oxetane, wherein the cyclopropyl, cyclobutyl, and oxetene are optionally substituted with 1, 2, or 3 groups independently selected from —OH, C1-C4 alkyl, and C1-C4 alkoxy; or
Q 1 is N, and R 2 is selected from halogen, —SCH 3 , C1-C8 acyclic alkyl, C2-C8 acyclic alkenyl, C1-C8 monohaloalkyl, C1-C8 polyhaloalkyl, C1-C8 alkoxyhaloalkyl, cyclopropyl, cyclobutyl, and oxetane, wherein the cyclopropyl, cyclobutyl, and oxetene are optionally substituted with 1, 2, or 3 groups independently selected from —OH, C1-C4 alkyl, and C1-C4 alkoxy;
Q 2 is a structure selected from:
each of R 3a and R 3b is independently selected from hydrogen, halogen, —OH, C1-C4 alkoxy, and C1-C4 alkyl; and
R 4 is halogen or —CN.
2 . The method of claim 1 , wherein the subject has a disorder associated with pantothenate kinase activity.
3 . The method of claim 2 , wherein the disorder is hyperglycemia, neurodegeneration, or diabetes.
4 . The method of claim 1 , wherein the subject has a disorder associated with a low level of coenzyme A.
5 . The method of claim 1 , wherein Q 1 is CH and R 2 is selected from C1-C8 acyclic alkyl, C2-C8 acyclic alkenyl, C1-C8 monohaloalkyl, C1-C8 polyhaloalkyl, and cyclopropyl; or Q 1 is N and R 2 is selected from halogen, C1-C8 acyclic alkyl, C2-C8 acyclic alkenyl, C1-C8 monohaloalkyl, C1-C8 polyhaloalkyl, and cyclopropyl; and Q 2 is a structure selected from:
6 . The method of claim 1 , wherein Q 2 is a structure selected from:
7 . The method of claim 1 , wherein Q 2 is a structure selected from:
8 . The method of claim 1 , wherein Q 1 is CH; and wherein R 2 is cyclopropyl, wherein the cyclopropyl is optionally substituted with 1, 2, or 3 groups independently selected from —OH, C1-C4 alkyl, and C1-C4 alkoxy.
9 . The method of claim 1 , wherein the compound is selected from:
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 1, 2021
From: SHARMA, LALIT KUMAR; LEE, RICHARD E.; ROCK, CHARLES O.; JACKOWSKI, SUZANNE; YUN, MI KYUNG; SUBRAMANIAN, CHITRA
To: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.
Reel/Frame 057360/0831 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 1, 2021
From: LIU, JIUYU
To: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.
Reel/Frame 057360/0950 →
Continuity (3)
Continuation
16307473
Provisional Application
62354012
· Jun 23, 2016
References Cited (111)
US 4216212A
· Flora et al.
· 1980
[cited by applicant]
US 5939462A
· Connell et al.
· 1999
[cited by applicant]
US 7754724B2
· Lorsbach et al.
· 2010
[cited by applicant]
US 8153633B2
· Austin et al.
· 2012
[cited by applicant]
US 8227467B2
· Kyle et al.
· 2012
[cited by applicant]
US 8618097B2
· Bencsik et al.
· 2013
[cited by applicant]
US 8975398B2
· Hansen et al.
· 2015
[cited by applicant]
US 20060035884A1
· Neitzel et al.
· 2006
[cited by applicant]
US 20090306100A1
· Barbosa et al.
· 2009
[cited by applicant]
US 20100041663A1
· He et al.
· 2010
[cited by applicant]
US 20110021530A1
· Billich et al.
· 2011
[cited by applicant]
US 20130072497A1
· Lorsbach et al.
· 2013
[cited by applicant]
US 20220363667A1
· Tanaka et al.
· 2022
[cited by applicant]
WO WO2003105853A1
· 2003
[cited by applicant]
WO WO2004011441A1
· 2004
[cited by applicant]
WO WO2004058754A1
· 2004
[cited by applicant]
WO WO2005011653A2
· 2005
[cited by applicant]
WO WO2005056015A1
· 2005
[cited by applicant]
WO WO2009106991A2
· 2009
[cited by applicant]
WO WO2010007120A1
· 2010
[cited by applicant]
WO WO2013004642A1
· 2013
[cited by applicant]
WO WO2016168619A1
· 2016
[cited by applicant]
WO WO2017223474A1
· 2017
[cited by applicant]
WO WO2019133632A1
· 2019
[cited by applicant]
WO WO2019133634A1
· 2019
[cited by applicant]
WO WO2019133635A1
· 2019
[cited by applicant]
WO WO2022133034A1
· 2022
[cited by applicant]
Subramanian, et al.; “Pantothenate kinase activation relieves coenzyme A sequestration and improves mitochondrial function in mice with propionic acidemia”; 2021; Sci. Transl. Med.; 13, eabf5965; pp. 1-13 (Year: 2021).
[cited by examiner]
Database Biosis, Accession No. PREV198631080811, 1986, Abstract.
[cited by applicant]
Database Biosis, Accession No. PREV200100537451, Oct. 2001, Abstract.
[cited by applicant]
European Search Report for EP Application No. 18894179.3, mailed Jul. 19, 2021, 7 pages.
[cited by applicant]
European Search Report for EP Application No. 18895007.5, mailed Aug. 19, 2021, 9 pages.
[cited by applicant]
Horig et al., From bench to clinic and back: Perspective on the 1st IQPC Translational Research Conference, Journal of Translational Medicine, Dec. 20, 2004, vol. 2, p. 44.
[cited by applicant]
Leeson et al., The influence of drug-like concepts on decision-making in medicinal chemistry, Nature Review Drug discovery, Nov. 2007, vol. 6, pp. 881-890.
[cited by applicant]
Leonardi et al., Coenzyme A: Back in action, Progress in Lipid research, 2005, 44(2-3):125-53.
[cited by applicant]
Pratini et al., Treatment of Classic Pantothenate Kinase-Associated Neurodegeneration (PKAN) with Deferiprone and Intrathecal Baclofen, American Journal of Physical Medicine & Rehabilitation, Aug. 2013, vol. 98, pp. 728…
[cited by applicant]
Rinaldo et al., Effect of treatment with glycine and 1-carnitine in medium-chain acyl-coenzyme a dehydrogenase deficiency, Journal of Pediatrics, Mosby-Year Book, St. Louis, Mo, Apr. 1, 1993, vol. 122, No. 4, pp. 580-58…
[cited by applicant]
Rock et al. (2002) The murine pantothenate kinase (Pank1) gene encodes two differentially regulated pantothenate kinase isozymes, Gene 291: 35-43.
[cited by applicant]
Schäfer et al., Failure is an option: learning from unsuccessful proof-of-concept trials, Drug Discovery Today, Nov. 2008, vol. 13, Nos. 21/22, pp. 913-916.
[cited by applicant]
Shultz, Setting expectations in molecular optimizations: Strengths and limitations of commonly used composite parameters, Bioorganic & Medicinal Chemistry Letters, 2013, 23, 5980-5991.
[cited by applicant]
Zhang et al., Feedback Regulation of Murine Pantothenate Kinase 3 by Coenzyme A and Coenzyme A Thioesters, The Journal of Biological Chemistry, Sep. 23, 2005, vol. 280, pp. 32594-32601.
[cited by applicant]
Database Registry (STN) Registry No. 1954499-65-0, entered Jul. 18, 2016.
[cited by applicant]
Database Registry (STN) Registry No. 1956298-43-3, entered Jul. 20, 2016.
[cited by applicant]
Cecil Textbook of Medicine, edited by Bennet, J.C., and Plum F., 1996, 20th edition, vol. 1, pp. 1004-1010.
[cited by applicant]
Cohen, The development and therapeutic potential of protein kinase inhibitors, Current Opinion in Chemical Biology, 1999. 3:4459-465.
[cited by applicant]
Dansie et al. (2014) Physiological roles of the pantothenate kinases, Biochem. Soc. Trans. 42:1033-1036.
[cited by applicant]
Dermer et al., Another Anniversary for the War on Cancer, BioTechnology, 1994, 12:320.
[cited by applicant]
European Search Report and Written Opinion by the European Patent Office for EP Application No. 17816310.1, mailed on Oct. 29, 2019, 9 pages.
[cited by applicant]
Freshney et al., Culture of Animal Cells, a Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p. 4.
[cited by applicant]
Garcia et al. (2012) Germline deletion of pantothenate kinases 1 and 2 reveals the key roles for CoA in postnatal metabolism, PLoS one 7: e40871.
[cited by applicant]
Jackowski and Rock (1981) Regulation of coenzyme A biosynthesis. J. Bacteriol. 148: 926-932.
[cited by applicant]
Johnson et al. (2004) Mitochondrial localization of human PANK2 and hypotheses of secondary iron accumulation in pantothenate kinase-associated neurodegeneration, Ann. N Y. Acad. Sci. 1012: 282-298.
[cited by applicant]
Kotzbauer et al. (2005) Altered neuronal mitochondrial coenzyme A synthesis in neurodegeneration with brain iron accumulation caused by abnormal processing, stability, and catalytic activity of mutant pantothenate kinas…
[cited by applicant]
Kuo et al. Deficiency of pantothenate kinase 2 (Pank2) in mice leads to retinal degeneration and azoospermia. Hum. Mol. Genet. (2005), 14, 49-57.
[cited by applicant]
Leeson, et al. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat. Rev. Drug. Discov. 2007, 6, 881-890.
[cited by applicant]
Leonardi et al. (2005) Coenzyme A: back in action, Prog. Lipid Res. 44(2-3):125-53.
[cited by applicant]
Leonardi et al. (2007) Localization and Regulation of Mouse Pantothenate Kinase 2, FEBS Lett. 581:4639-4644.
[cited by applicant]
Leonardi et al. (2010) Pantothenate Kinase 1 is required to support the metabolic transition from the fed to the fasted state, PloS one 5: el1107.
[cited by applicant]
Leonardi et al. (2014) Pank 1 deletion in leptin-deficient mice reduces hyperglycemia and hyperinsulinaemia and modifies global metabolism without affecting insulin resistance, Diabetologia 57: 1466-1475.
[cited by applicant]
Pubmed Compound Summary for CID 110727414, ‘AKOS027640281’, U.S. National Library of Medicine, (2016), (https://pubchem.ncbi.nlm.nih.gov/compound/110727414); p. 3.
[cited by applicant]
Pubmed Compound Summary for CID 53621124, ‘MolPort-020-021-215’, U.S. National Library of Medicine, (2011),(https://pubchem.ncbi.nlm.nih.gov/compound/53621124); p. 3.
[cited by applicant]
PubChem Compound Summary For CID 75373203 Create Date: Jul. 12, 2014 (Jul. 12, 2014) Date Accessed: Feb. 20, 2019 (Feb. 20, 2019); p. 4, compound listed.
[cited by applicant]
PubChem Compound Summary For CID 121060331 deposited on Jun. 17, 2016 (Jun. 17, 2016) pp. 1-10. p. 3.
[cited by applicant]
Sabatti et al., Genome-wide association analysis of metabolic traits in a birth cohort from a founder population. Nature Genet. (2009), 41, 35-46.
[cited by applicant]
Sharma et al. (2015) A High-Throughput Screen Reveals New Small-Molecule Activators and Inhibitors of Pantothenate Kinases, Med. Chem. 58: 1563-1568.
[cited by applicant]
Shultz, M. D. Setting expectations in molecular optimizations: Strengths and limitations of commonly used composite parameters. Bioorg. Med. Chem. Lett. 2013, 23, 5980-5991.
[cited by applicant]
Tafesse et al. ‘Synthesis and evaluation of pyridazinylpiperazines as vanilloid receptor 1 antagonists’ Bioorganic & Medicinal Chemistry Letters, (2004) vol. 14, p. 5513-5519; p. 5515.
[cited by applicant]
Zhang et al. (2005) Feedback regulation of murine pantothenate kinase 3 by coenzyme A and coenzyme A thioesters, J. Biol. Chem. 280: 32594-32601.
[cited by applicant]
Zhang et al. (2006) Biochemical Properties of Human Pantothenate Kinase 2 Isoforms and Mutations Linked to Pantothenate Kinase-associated Neurodegeneration, J. Biol. Chem. 281:107-114.
[cited by applicant]
Zhou et al. (2001) A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome, Nat. Genet. 28: 345-349.
[cited by applicant]
International Search Report and Written Opinion by the International Searching Authority for International Application No. PCT/US2017/039037, mailed Nov. 9, 2017, 9 pages.
[cited by applicant]
International Preliminary Report on Patentability by the International Searching Authority for International Application No. PCT/US2017/039037, mailed Dec. 25, 2018, 6 pages.
[cited by applicant]
International Search Report and Written Opinion the International Searching Authority for International Application No. PCT/US2018/067536, mailed on Mar. 21, 2019, 6 pages.
[cited by applicant]
International Search Report and Written Opinion by the International Searching Authority for International Application No. PCT/US2018/067538, mailed on Mar. 27, 2019, 8 pages.
[cited by applicant]
International Search Report and Written Opinion by the International Searching Authority for International Application No. PCT/US2018/067539, mailed on Mar. 27, 2019, 8 pages.
[cited by applicant]
Chen et al., Methylmalonic acidemia: Neurodevelopment and neuroimaging, Frontiers in Neuroscience, Jan. 26, 2023, vol. 17, p. 1-9.
[cited by applicant]
Forny et al., Novel Mouse Models of Methylmalonic Aciduria Recapitulate Phenotypic Traits with a Genetic Dosage Effect*, Sep. 16, 2023, vol. 291, No. 39, pp. 20503-20573.
[cited by applicant]
Rivera-Barahona et al., Identification of 34 novel mutations in propionic acidemia: Functional characterization of missense variants and phenotype associations, Molecular Genetics and Metabolism, 2018, vol. 125, pp. 266…
[cited by applicant]
Yu et al., Different mutations in the MMUT gene are associated with the effect of vitamin B12 in a cohort of 266 Chinese patients with mut-type methylmalonic acidemia: A retrospective study, Molecular Genetics & Genomic…
[cited by applicant]
International Search Report for International Application No. PCT/US2021/063717, mailed May 12, 2022, 4 pages.
[cited by applicant]
Mitchell et al., Hereditary and acquired diseases of acyl-coenzyme A metabolism, Molecular Genetics and Metabolism, 2008, vol. 94, pp. 415.
[cited by applicant]
National Institute of Neurological Disorders and Stroke, Refsum Disease Information Page, https://www.ninds.nih.gov/Disorders/All-Disorders/Refsum-Disease-Information-Page), 2019, 4 pages.
[cited by applicant]
Waack et al., L-Malate's Plasma and Excretion Profile in the Treatment of Moderate and Severe Hemmorrhagic Shock in Rats, BioMed Research International, 2016, vol. 2016, 9 pages.
[cited by applicant]
Yang et al., Hereditary diseases of coenzyme A thioester metabolism, Biochemical Society Transactions, 2019, vol. 47, pp. 149-155.
[cited by applicant]
Written Opinion for International Application No. PCT/US2021/063717, mailed May 12, 2022, 6 pages.
[cited by applicant]
CAS Registry No. 1183793-26-1, Entered STN Sep. 13, 2009.
[cited by applicant]
Chemical Abstract Registry No. 953135-76-7, entered STN CAS Online Nov. 13, 2007.
[cited by applicant]
Ali, E. M. H., et al. Thieno[2,3-d]pyrimidine as a promising scaffold in medicinal chemistry: Recent advances. Bioorganic & medicinal chemistry, 2019. vol. 27(7): 1159-1194. Published online on Feb. 21, 2019. (Year: 201…
[cited by applicant]
Bassyouni, F.A. et al. Synthesis and anticancer activity of some new pyridine derivatives. Res Chem Intermed, 2012. vol. 38: 1291-1310. (Year: 2012).
[cited by applicant]
Bhat A. R. Biological Activity of Pyrimidine Derivativies: A Review. Organic & Medicinal Chem IJ, 2017. vol. 2(2): 555581. (Year: 2017).
[cited by applicant]
CAS Registry No. 1357881-66-3 (Entered STN Registry Feb. 28, 2012). (Year: 2012).
[cited by applicant]
Elmeligie, S., et al. Design and Synthesis of Pyridazine Containing Compounds with Promising Anticancer Activity. Chemical & pharmaceutical bulletin, 2017. vol. 65(3): 236-247. (Year: 2017).
[cited by applicant]
Henderson, E. D. et al. Design, Synthesis and Evaluation of Novel N-Substituted-[Benzoylamino]-5-Ethyl-1,2,3,6-Tetrahydropyridines as Potential Anti-Cancer Agents. Madridge journal of pharmaceutical research, 2019. vol.…
[cited by applicant]
Holden-Dye, L. et al. Anthelmintic drugs and nematicides: studies in Caenorhabditis elegans. WormBook : the online review of C. elegans biology, 2014: 1-29. (Year: 2014).
[cited by applicant]
Koshio, H., et al. Synthesis and biological activity of novel 1,4-diazepane derivatives as factor Xa inhibitor with potent anticoagulant and antithrombotic activity. Bioorganic & medicinal chemistry, 2004. vol. 12(9): 2…
[cited by applicant]
Patani, G. A. et al. Bioisosterism: A Rational Approach in Drug Design. Chemical reviews, 1996, vol. 96, 8: 3147-3176. (Year: 1996).
[cited by applicant]